We have previously shown that hypercapnic chemoreflex in prepro-orexin knockout mice (ORX-KO) is attenuated during wake but not sleep periods. In that study, however, hypercapnic stimulation had been chronically applied for 6 hrs because of technical difficulty to change the composition of the inspired gas mixture without distorting the animal's vigilance states. Here we examine possible involvement of orexin in acute respiratory chemoreflex during wake periods.
examine possible involvement of orexin in acute respiratory chemoreflex during wake periods.
Ventilation was recorded together with electroencephalography and electromyography before and after intracerebroventricular administration of orexin or an orexin receptor antagonist, SB-334867. A hypercapnic (5 or 10% CO 2 ) or hypoxic (15 or 10% O 2 ) gas mixture was introduced into the recording chamber for 5 min. Respiratory parameters were analyzed only for quiet wakefulness. When mice breathed normal room air, orexin-A and orexin-B but not vehicle or SB-334867 increased minute ventilation in both ORX-KO and wild-type (WT) mice. As 
Introduction
Orexins (orexin-A and orexin-B), also named hypocretins (hypocretin 1 and hypocretin 2), were first discovered as hypothalamic neuropeptides facilitating appetite and consciousness (36) .
Further studies showed that orexins modulate circulation (8, 28, 44) , respiration (40, 42) , and analgesia (34, 37) . Orexinergic neurons exist only in the dorsal part of the hypothalamus including the dorsomedial hypothalamus, perifornical area, and lateral hypothalamus, but their axons project widely to various regions of the central nervous system (17, 22, 24) . These hypothalamic areas are reported to be responsible for integrating defense response against stressors (7, 14, 27, 39) .
These physiologic and anatomic features taken together suggest that orexinergic neurons play a role in integrating defense response. Respiration, an important component of defense response, is also likely to be controlled by orexins. Actually, physiological studies have indicated that orexins increased ventilation (40, 42) and orexin deficiency caused attenuated ventilatory responses in fight-or-flight behavior (15, 43, 44) . In addition, anatomical studies demonstrated the connections between orexinergic neurons and respiratory motor neurons, such as the hypoglossal nucleus (11) , pre-Bötzinger complex, and phrenic motor neurons in the spinal cord (40) .
We also found that prepro-orexin knockout (ORX-KO) mice have attenuated hypercapnic chemoreflex during wake but not sleep periods (21) . This observation is consistent with the notion that the activity of orexinergic neurons is higher during wake than sleep periods (16, 19) .
In that study, however, hypercapnic stimulation had been applied chronically for 6 hrs because of technical difficulty to change the composition of the inspired gas mixture without distorting the vigilance states of animals.
Some previous findings have suggested that the hypothalamus could modulate ventilation (12, 13, 32) . For example, Horn and Waldrop (13) demonstrated that the posterior hypothalamus Page 3 of 31 exerted an excitatory effect on both hypoxic and hypercapnic ventilatory responses. On the contrary, Hinrichsen, et al. (12) demonstrated that a posterior hypothalamus lesion increased ventilatory responses to hypoxia. These seemingly opposite findings concerning hypoxic ventilatory responses might be due to the fact that the hypothalamus is a heterogeneous structure.
In this context, the use of ORX-KO mice allows us to investigate the hypothalamic area in a chemically-specific manner.
In the present study, therefore, we examined whether our previous findings could be generalized to acute chemoreceptor reflex and whether orexin-related drugs could affect chemoreflex during wake periods in ORX-KO mice and their wild-type (WT) littermates. 
METHODS

Animals
ORX-KO mice with mixed genetic background of 129/Sv and C57BL/6 were generated as reported previously (5) and backcrossed to C57BL/6 more than 9 times. They totally lacked orexin-A and orexin-B because both peptides are the product of the one precursor, prepro-orexin.
The animals were maintained in heterozygotes and crossed to obtain null mutants and WT littermates. The genotype of ORX-KO mice was identified by PCR on DNA extracted from the tail as previously reported (15) . Mice used in this study were 28-to 44-week-old male ORX-KO homozygotes (n=24, body weight 36±1 g) and WT (n=28, body weight 34±1 g) mice. Body weight of ORX-KO mice tended to be higher than WT mice but there was no statistical difference. The animals were kept in an air-conditioned room (20-25°C) under a 12-hour light/dark cycle with lights on from 7 a.m. Mice were provided food and water ad libitum. All experimental procedures were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Use Committee of Chiba University Graduate School of Medicine.
Simultaneous Measurement of Respiration and Vigilance States
Methods of surgery, recording of electroencephalography (EEG), electromyography (EMG), and respiration, and definition of vigilance states for this study were the same as those for our previous studies (20, 21) except that an additional cannula was implanted for intracerebroventricular (icv) administration of the drugs. In brief, mice were surgically implanted with electrodes for EEG and EMG and an icv guide cannula (C315GS-5/2.5; Plastics One, Roanoke, VA, USA) to the lateral ventricle (1 mm lateral to Bregma, 2.5 mm deep in the skull) (10) under isoflurane anesthesia at least 7 days prior to the experiments. An antibiotic, cefazolin (100 mg/kg), was injected subcutaneously before the surgery. On the experimental day, the Nine ORX-KO and 6 WT mice were used. Room air at a flow rate of 0.6 L/min was supplied through the inflow of the chamber. Sufficient bedding material and food were provided in the chamber. Air-tightness was confirmed by checking all the connections to the chambers with soap water. Each experiment was started around 10:00 a.m. when mouse was put into the chamber and allowed to adapt to the environment for more than one hour. The appearance of sleep, proven by the EEG and EMG recordings and behavior, was considered the sign of acclimatization.
After acclimatization, the baseline parameters were collected when the mouse breathed room air for 20 minutes (termed "room air-1"). Next, the mouse was taken out of the chamber, administered with artificial cerebrospinal fluid (ACSF) through the icv cannula, and immediately returned to the chamber. Another 20 min period in room air (termed "room air-2") was allowed to measure the effect the drug administration on baseline parameters. After this period, hypercapnic gas mixture of 5% CO 2 -21% O 2 and residual nitrogen was introduced into the chambers. When the CO 2 concentration at the outlet port reached the target concentration (usually within 2 min after introduction), a 5-min recording was made. Subsequently, hypercapnic gas of 10% CO 2 -21% O 2 and residual nitrogen was introduced and another 5-min recording was taken. Thereafter, the mouse breathed room air for 20 min (termed "room air-3").
After the experiments with hypercapnic gases, hypoxic gas of 15% O 2 with residual nitrogen and hypoxic gas of 10% O 2 with residual nitrogen were introduced into the chambers. A 5-min recording was taken for each hypoxic condition. There was a 20-min interval with room air breathing (termed "room air-4") between the hypoxic stimulations. Finally, the mice breathed room air for 20 minutes for recovery (termed "room air-5"). In total, 9 sequential data values (during room air-1 before icv, room air-2 after icv, 5% CO 2 , 10% CO 2 , room air-3, 15% O 2 , room air-4, 15% O 2 , and room air-5) were obtained in each experiment. Calibration gas of 60 µL was introduced with a pipette into the reference chamber before the mouse was taken out of the chamber.
The same protocol was repeated with orexin-A and orexin-B in a random sequence for each animal, with at least a two-day interval between experiments.
Experiment 2: Orexin receptor blockade
Only WT mice were used (n=7). The experimental protocol was the same as that of Experiment 1, except that the administered drugs were ACSF, vehicle, and orexin receptor 1 antagonist, SB-334867 (29, 37 ).
Blood Gas Analysis and CO 2 Production
In a separate group of mice (n=15 for each genotype), a catheter was implanted into the right carotid artery of each animal under isoflurane anesthesia. A hole was made in the skull (1 mm lateral to the Bregma) of the animal for icv administration of the drugs. After a recovery period of more than 3 hrs, the mouse was placed in the body plethysmography chamber and breathed room air for 20 min. Next, the mouse was taken out of the chamber and administered ACSF, orexin-A, or orexin-B through the hole in the skull using a microsyringe, which needle tip lay 3.5 mm deep in the skull. Immediately after the administration, the animal was returned to the chamber and another 20 min period of room air was allowed. At the end of this period, up to 70
Sl of arterial blood was drawn from the indwelling catheter of which the distal end had been exteriorized from the chamber through a small port. After completion of the first blood sampling, the chamber was filled with the 10% CO 2 -21% O 2 and residual nitrogen gas mixture for 10 min.
A second blood sampling was performed while the animals were breathing the hypercapnic gas mixture. Only one drug was administered in each animal in this experiment.
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Agents Administered
ACSF, orexin-A (Peptide Institute, Osaka, Japan) (3 nmol) and orexin-B (3 nmol) in ACSF, vehicle (see below), and orexin receptor 1 antagonist SB-334867 (Tocris Bioscience, Bristol, UK) (30 nmol) dissolved in the vehicle were prepared and administered in a volume of 2 µL into the lateral ventricle through the icv internal cannula (C315IS-5/2.5; Plastic One), which was fitted into the guide cannula with 1 mm projection.
Orexin receptor-1 antagonist SB334867 is hydrophobic and insoluble in ACSF. Although dimethyl sulfoxide (DMSO) is sometimes used as a solvent for hydrophobic substances and recommended by the manufacturer of SB334867, it interferes with the sleep architecture (4). In addition, our preliminary study showed icv administration of 50% and higher concentrations of DMSO caused severe seizure, confirmed by EEG and muscle twitching. To avoid such problems, we dissolved SB334867 first in DMSO (to a concentration of 50 mM) and then diluted the solution using 45% (2-hydroxypropyl)--cyclodextrin in ACSF to make 15 mM SB334867.
Without using -cyclodextrin, SB334867 was precipitated out of 30% DMSO in ACSF. Neither the vehicle (31.5% -cyclodextrin -30% DMSO in ACSF) nor 30% DMSO in ACSF had affected sleep or caused any seizure or any other apparent abnormality in our preliminary study.
The icv administration of 3 nmol of orexin in 2 µL ACSF would exceed the physiological concentration found in the cerebral spinal fluid (25, 41) . Possible effects of volume and concentration on vigilance state and respiration cannot be excluded. However, other studies of icv orexin administration have adopted similar doses, and the changes in the concentration within the physiological range did not affect the so far observed parameters (6, 18, 42) .
Therefore, we decided to use a pharmacological dose of 3 nmol for convenience of comparison. 
RESULTS
Vigilance States and Motor Activity
Administration of ACSF transiently increased the AW periods in WT mice for no more than 20 min (Fig. 1 A, E) . Thereafter, AW periods progressively decreased towards the end of the experiment and were not apparently affected by hypercapnic or hypoxic stimuli. On the other hand, QW periods were hardly affected by animal handling and/or volume injection but were largely increased by severe chemo-stimuli (10% CO 2 and 10% O 2 ; Fig. 1 ). Comparing WT and ORX-KO mice, AW time in the ORX-KO mice was significantly (p<0.05) shorter than that in the WT mice. However, no difference was observed in QW time.
Administration of orexin-A dramatically increased AW periods and QW periods moderately (Fig. 1 B) . Total wake time (AW plus QW periods) exceeded 90% even at 2 hrs after injection, when the last measurement during room air breathing was performed. In comparison to ACSF, orexin-A significantly (p<0.05) increased both AW and QW periods. Administration of orexin-B also increased AW and QW periods (Fig. 1 C) . However, the effect of orexin-B was shorter-lasting than that of orexin-A. Therefore, difference between AW (or QW) periods after ACSF and that after orexin-B did not reach statistical significance. After administration of orexin-A or orexin-B, there was no statistical difference in AW between ORX-KO and WT mice or in QW between ORX-KO and WT mice, indicating normally preserved orexin receptors in ORX-KO mice.
The effects of SB334867 and its vehicle on AW and QW periods were not different from those of ACSF (Fig. 1 D-F) .
We also analyzed the animal's motor activity during the AW period (Fig. 2) . Inhalation of CO 2 increased motor activity in both WT and ORX-KO mice, irrespective of the injected drugs.
Although orexin-A apparently increased motor activity in ORX-KO mice, the difference did not reach statistical significance. There was no difference between WT and ORX-KO mice as to the Taken together, these results showed that orexin mainly affected the wake duration and less did the motor activity per AW time.
Effects on Basal Breathing
Before icv drug administration, spontaneous breathing was not different between WT and ORX-KO mice or among treatment groups (Fig. 3) . Administration of orexin-A significantly increased minute ventilation in both ORX-KO (UMV=67±18 %, n=9) and WT mice (43±14 %, n=6). In a similar manner, administration of orexin-B increased ventilation in both ORX-KO (106±13 %) and WT mice (83±28 %). Orexin-B had significantly stronger effects than orexin-A in both genotypes. There was no significant difference between MV in ORX-KO and MV in WT after the treatment of any drug.
Neither ACSF (UMV=9±10 % for WT in Experiment 1; 2±5 % for ORX-KO; 15±8 % for WT in Experiment 2, n=7), SB334867 (5±4 %), nor its vehicle (10±6 %) influenced spontaneous ventilation.
Hypercapnic Chemoreflex
In all of the treatment groups, inhalation of both 5% and 10% CO 2 progressively increased MV (Figs. 3 and 4) . ) but not its vehicle attenuated hypercapnic chemoreflex in WT mice (Fig. 3 C) .
Hypoxic Chemoreflex
As was the case in hypercapnic chemoreflex, inhalation of 15% and 10% O 2 progressively increased MV in all of the treatment groups (Figs. 3 and 5) , although the increases were not as prominent as those in the hypercapnia group . Similar analysis to that employed for the hypercapnic response revealed that the slope of the hypoxic chemoreflex was not affected by orexin deficiency or any drug treatment.
Blood Gas and CO 2 Production
Possible effect of orexin on PaCO 2 and CO 2 production was evaluated using another set of mice. In the WT mice, icv administration of orexin-A and -B slightly increased PaO 2 and decreased PaCO 2 (Table 1) . However, these changes did not reach statistical significance (p=0.18
for PaO 2 and p=0.15 for PaCO 2 ). On the other hand, inhalation of 10% CO 2 significantly increased PaO 2 and PaCO 2 . There was no interaction between the drugs (ACSF, orexin-A, or -B) and the gas conditions (room air or 10% CO 2 ). The same was true in the ORX-KO mice.
Moreover, there was no difference between the blood gases in WT mice and those in the ORX-KO mice for any particular condition.
Neither orexin-A nor -B affected CO 2 production in either the WT or ORX-KO mice (Table   1 ). CO 2 production in the ORX-KO mice tended to be smaller than that in the WT mice, indicating lower basal metabolism in the ORX-KO mice. However, the difference did not reach 
DISCUSSION
In this study, we investigated the role of orexins in respiratory chemoreflex. The results showed: 1) ORX-KO mice attenuated respiratory chemoreflex to hypercapnic but not hypoxic gases; 2) supplementation of orexin-A or orexin-B partially restored the attenuated chemoreflex in ORX-KO mice; and 3) an orexin receptor-1 antagonist, SB334867, weakened hypercapnic chemoreflex in the WT mice. These three lines of evidence clearly support our hypothesis that orexin participates in hypercapnic chemoreflex during wake periods in mice.
In our previous study (21), we showed that hypercapnic but not hypoxic chemoreflex in ORX-KO mice was blunted only when the mice were awake even though the baseline ventilation was not different between the ORX-KO and WT littermates; it is worth noting that identical results were obtained in this study despite some differences in the experimental setup. First, we used chronic chemoreceptor stimulations (for 6 hrs) in the previous study because we had put priority on observing vigilance states with minimal perturbations rather than study chemoreflex.
Second, we used a set of animals backcrossed 5 times to C57BL/6 in the previous study, whereas more than 9 times in the current study. Third, ventilation was compared using naïve mice in the previous study and after pretreatment with ACSF in the current study. Since these differences did not affect the conclusion, orexin deficiency in mice conceivably distorts the hypercapnic chemoreflex during wake periods.
Awake-promoting effect of orexins have been repeatedly reported in normal animals (1, 30, 36) and in orexin-deficient mice (18) . Such effect is likely to result in stimulating respiration. If so, orexin-A would exert stronger or at least similar ventilation-promoting effect to that with orexin-B because the awake-promoting effect of orexin-A is stronger and longer-lasting than that of orexin-B (Fig. 1) . On the contrary, orexin-B had stronger ventilation-promoting effect than orexin-A (Fig. 3) . Moreover, the ventilation-promoting effect of orexin-A can be observed under anesthetized conditions (42) . Thus, the ventilation-promoting effect of orexins cannot be fully explained by their awake-promoting effect. Orexins' awake-promoting effect seemed to result mainly from their action on alertness rather than on motor activity (Fig. 2) or metabolism (Table   1 ). Detailed analysis of the animals' behavior (such as orientation/exploring vs. motor hyperactivity) might support such characterization. Unfortunately, however, we did not record the animals' behavior in this study.
The current experiment showed that orexin-B had a stronger effect than orexin-A on increasing spontaneous ventilation. Orexin-B mainly acts on orexin receptor-2 (26), thus orexin receptor-2 appears to have played a larger part in the current results. On the other hand, blockage of orexin receptor-1 by SB334867 weakened hypercapnic chemoreflex of the WT mice, indicating that orexin receptor-1 is necessary for chemoreflex control. According to the results of this study, we speculate that blockade of orexin receptor-2 is likely to weaken hypercapnic chemoreflex to a larger degree. This is a question worth further investigating when a specific antagonist to orexin receptor-2 becomes available.
ORX-KO mice did not respond differently from WT mice when they breathed hypoxic gas mixtures. Therefore, orexins are possibly not involved in respiratory hypoxic chemoreflex. On the other hand, the mouse strain we used (C57BL/6) is not sensitive to hypoxic stimulation (31) .
The slope of hypoxic response after ACSF pretreatment was not as prominent as that of hypercapnia (compare the scale difference in the vertical axis between Figs. 4 and 5) . Therefore, the difference between ORX-KO and WT mice may be too small to be detected. Orexin supplementation also did not cause any significant difference for the same reason. Backcrossing to a more hypoxia-sensitive strain such as DBA/2J (31) may solve this issue.
The chemoreflex-promoting effect of orexins may be relevant to respiratory augmentation during many (patho)physiological conditions such as exercise, fight-or-flight response, and hyperventilation syndrome. Actually, we previously showed that hypothalamic stimulation resulted in attenuated respiratory responses in orexin-deficient mice (15, 43) . In the same animal model, stress-induced increases in blood pressure and heart rate, and stress-induced analgesia were also blunted. During fight-or-flight response, chemoreflex is augmented (33) whereas baroreflex is attenuated (23) . We confirmed the latter phenomenon was blunted in orexin neuron-ablated mice, another animal model of orexin deficiency (43) . Therefore, it seems reasonable to speculate possible contribution of orexin in respiratory augmentation during the fight-or-flight response, although this issue awaits the findings of further experiments.
Orexin neurons were activated by hypoglycemia (3) and inhibited by glucose (2, 38) .
Therefore, hyperventilation during hypoglycemia may be related to not only metabolic acidosis but also to the respiratory-promoting effect of orexin. During the revising process of this manuscript, a paper appeared showing activation of the orexinergic neurons in hypothalamic slice preparations by CO 2 and H + (35) . This is in direct support of our hypothesis and may explain hyperventilation during hypoglycemia, although the precise physiological relevance should be further studied in vivo.
In conclusion, our results taken together with those of other previous studies indicate that orexins are involved in integrity of overall ventilation control. To our knowledge, this is the first study to clearly demonstrate the involvement of orexin in respiratory chemoreflex using both loss-of-function (genetic and antagonistic) and gain-of-function (agonistic) strategies. There was no difference among pretreatments (vehicle, ORX-A, or ORX-B). *p<0.01 vs.
